MSB 5.38% $1.37 mesoblast limited

Ann: MSB Highlights Key 2019 Priorities at U.S. Biotech Showcase, page-2

  1. 572 Posts.
    lightbulb Created with Sketch. 28

    In 2019, Mesoblast Ltd  (MSB) plans to work diligently with the U.S. Food and Drug Administration (FDA) to submit a rolling Biologics License Application for use of remestemcel-L in treating acute graft versus host disease (aGVHD) in children, and will execute on the product candidate’s market access and commercialization strategy  


    http://crweworld.com/article/news-provided-by-globenewswire/930707/mesoblast-highlights-2019-key-priorities-for-its-leading-cellular-medicines-pipeline-at-biotech-showcase-in-san-francisco
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.37
Change
0.07(5.38%)
Mkt cap $658.1M
Open High Low Value Volume
$1.33 $1.37 $1.30 $1.035M 773.8K

Buyers (Bids)

No. Vol. Price($)
2 8817 $1.36
 

Sellers (Offers)

Price($) Vol. No.
$1.37 51879 1
Last update - 16.10pm 18/01/2019 (20 minute delay) ?
(live)
Last
$1.37
  Change
0.07 ( 4.87 %)
Open High   Low Volume
$1.31 $1.37   $1.30 138757
Last updated 15.59pm 18/01/2019 (live) ?
MSB (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.